Biweekly or Monthly Injections of Pegelated Beta Interferon Found Effective in Relapsing MS

Press release (warning: contains pharma corporatespeak) here.

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Published on January 28, 2013 at 2:56 AM ·

Peginterferon beta-1a reduced the risk of 12-week confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS) by 38 percent in both dosing arms (p<0.04).

Peginterferon beta-1a reduced the proportion of patients who relapsed by 39 percent in the once every two-week dosing arm (p<0.001) and by 26 percent in the once every four-week dosing arm (p<0.03).

Peginterferon beta-1a reduced the number of new or newly enlarging T2-hyperintense lesions on brain MRI scans by 67 percent in the once every two-week dosing arm (p<0.001) and by 28 percent in the once every four-week dosing arm (p<0.001).

In ADVANCE, both dosing regimens showed favorable safety and tolerability profiles. The overall incidence of SAEs and AEs was similar among the peginterferon beta-1a and placebo groups. The most common SAE was infections, which was balanced across all treatment groups (≤1 percent per group).

No comments:

Post a Comment

Prospective Study: Concussion Affects Menstrual Patterns in Adolescent and Young Women

Severe traumatic brain injury is a well-documented cause of secondary amenorrhea (lack of menstrual periods after menses has begun) in y...